Mint Tower Capital Management B.V. Makes New $1.58 Million Investment in Penumbra, Inc. $PEN

Mint Tower Capital Management B.V. acquired a new stake in Penumbra, Inc. (NYSE:PEN) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 5,019 shares of the company’s stock, valued at approximately $1,585,000.

Other large investors also recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Penumbra in the 2nd quarter valued at about $25,000. Larson Financial Group LLC lifted its position in Penumbra by 4,100.0% during the fourth quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after acquiring an additional 82 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in shares of Penumbra by 2,700.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock worth $26,000 after acquiring an additional 81 shares during the period. Motiv8 Investments LLC bought a new stake in shares of Penumbra during the fourth quarter worth approximately $27,000. Finally, Keating Financial Advisory Services Inc. acquired a new position in shares of Penumbra in the second quarter valued at approximately $31,000. 88.88% of the stock is owned by institutional investors.

Penumbra Price Performance

Penumbra stock opened at $321.58 on Friday. The firm has a market cap of $12.67 billion, a PE ratio of 79.01, a price-to-earnings-growth ratio of 1.99 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.75 and a quick ratio of 3.86. The stock’s fifty day moving average price is $320.71 and its two-hundred day moving average price is $326.86. Penumbra, Inc. has a one year low of $221.26 and a one year high of $362.41.

Penumbra (NYSE:PEN) last released its earnings results on Thursday, July 30th. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). Penumbra had a net margin of 10.67% and a return on equity of 10.50%. The company had revenue of $390.05 million for the quarter, compared to the consensus estimate of $389.64 million. During the same quarter in the previous year, the company posted $0.86 earnings per share. The business’s revenue was up 14.9% compared to the same quarter last year. As a group, research analysts expect that Penumbra, Inc. will post 5.02 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PEN. Evercore reiterated an “outperform” rating and set a $320.00 target price on shares of Penumbra in a research note on Monday, July 6th. Citigroup reduced their price target on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Penumbra in a research report on Friday, July 17th. Wall Street Zen raised Penumbra to a “hold” rating in a report on Saturday, May 9th. Finally, Zacks Research raised shares of Penumbra from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. Three analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat, Penumbra has an average rating of “Hold” and an average price target of $367.07.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.